Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

Research

Patient

Active, not recruiting

217-545-1394

Related Profiles

Sheena Hoadley

rmanka63@siumed.edu

Rylee Manka

https://clinicaltrials.gov/ct2/show/NCT04777331?term=PADOVA&draw=2&rank=2

Neurology